On January 22, 2016 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, reported that preclinical data for its lead immuno-oncology therapeutic candidate, CB-1158 has been selected for an oral presentation at the 2016 Keystone Symposia on Cancer Immunotherapy taking place January 24-28, 2016, in Vancouver, Canada (Press release, Calithera Biosciences, JAN 22, 2016, View Source;p=RssLanding&cat=news&id=2131434 [SID:1234508839]). CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a key immunosuppressive enzyme that limits T-cell proliferation in a wide range of tumors. Details for the presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells

Date: January 27, 2016

Session: Novel Immunotherapeutic Approaches and Antibody Therapies

Time: 5:00 p.m. -7:00 p.m. PT

Presenter: Susanne Steggerda, Ph.D., Calithera Biosciences

Abstract #3014

Poster Display: 7:30 a.m. – 10:00 a.m. PT